New Chief Financial Officer Appointed at Harvard Bioscience

Harvard Bioscience Announces CFO Transition

Cambridge, Mass., April 10, 2025 – Harvard Bioscience, Inc. (Nasdaq: HBIO), a global leader in the development, manufacture, and sale of research and clinical products, today announced that its Chief Financial Officer (CFO), Mark S. Einhorn, will be retiring from the company, effective June 30, 2025.

Mr. Einhorn has served as CFO of Harvard Bioscience since 2012, playing a key role in the company's strategic growth and financial success. During his tenure, the company has expanded its product offerings, strengthened its financial position, and increased its global presence.

"We are grateful for Mark's dedication and contributions to Harvard Bioscience over the past nine years," said Dr. James P. Robinson, President and CEO of Harvard Bioscience. "He has been a trusted advisor and a key member of our leadership team. We will miss his expertise and guidance, but we also recognize the opportunity to bring in fresh perspectives and skills to the CFO role as we continue to evolve and grow as a company."

The company has initiated a search for a new CFO, and a transition plan is in place to ensure a seamless continuation of Mr. Einhorn's responsibilities.

About Harvard Bioscience, Inc. Harvard Bioscience, Inc. is a global leader in the development, manufacture, and sale of research and clinical products. The company's products are used in a wide range of applications, including pharmaceutical and biotechnology research, clinical trials, and medical education. Harvard Bioscience is headquartered in Cambridge, MA, and has operations across the United States, Europe, and Asia. For more information, please visit www.harvardbioscience.com.